Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO OTCMKTS:RCAR NASDAQ:TELA NYSE:VAPO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.61+6.9%$0.65$0.50▼$1.39$35.74M1.4346,656 shs163,641 shsRCARRenovaCare$0.00$0.00▼$0.00N/A-129.861,458 shs1,725 shsTELATELA Bio$1.10+11.1%$0.75$0.50▼$2.20$44.32M1.3244,769 shs163,914 shsVAPOVapotherm$2.17$2.16$0.70▼$3.44$13.58M-1.11N/AN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+6.93%-0.08%-0.07%-9.30%-30.97%RCARRenovaCare0.00%0.00%0.00%0.00%+900.00%TELATELA Bio+11.11%+25.74%+59.42%+35.67%+15.79%VAPOVapotherm0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.61+6.9%$0.65$0.50▼$1.39$35.74M1.4346,656 shs163,641 shsRCARRenovaCare$0.00$0.00▼$0.00N/A-129.861,458 shs1,725 shsTELATELA Bio$1.10+11.1%$0.75$0.50▼$2.20$44.32M1.3244,769 shs163,914 shsVAPOVapotherm$2.17$2.16$0.70▼$3.44$13.58M-1.11N/AN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+6.93%-0.08%-0.07%-9.30%-30.97%RCARRenovaCare0.00%0.00%0.00%0.00%+900.00%TELATELA Bio+11.11%+25.74%+59.42%+35.67%+15.79%VAPOVapotherm0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.38781.87% UpsideRCARRenovaCare 0.00N/AN/AN/ATELATELA Bio 2.40Hold$2.20100.00% UpsideVAPOVapotherm 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TELA, CTSO, VAPO, and RCAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026TELATELA Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026TELATELA Bio Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$5.00 ➝ $3.003/26/2026CTSOCytosorbents D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/25/2026TELATELA Bio Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$1.25 ➝ $1.003/25/2026TELATELA Bio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.003/25/2026TELATELA Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $2.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.06M1.03N/AN/A$0.09 per share6.77RCARRenovaCareN/AN/AN/AN/AN/AN/ATELATELA Bio$80.28M0.61N/AN/A$0.16 per share6.88VAPOVapotherm$68.67M0.20N/AN/A($9.01) per share-0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.13N/AN/AN/A-22.12%-150.53%-32.75%5/13/2026 (Estimated)RCARRenovaCareN/AN/AN/AN/AN/AN/AN/AN/AN/ATELATELA Bio-$38.83M-$0.83N/AN/AN/A-48.37%-433.58%-53.00%5/12/2026 (Estimated)VAPOVapotherm-$58.19M-$8.51N/AN/AN/A-76.74%N/A-68.08%N/ALatest TELA, CTSO, VAPO, and RCAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CTSOCytosorbents-$0.06N/AN/AN/A$9.40 millionN/A5/12/2026Q1 2026TELATELA Bio-$0.14N/AN/AN/A$18.60 millionN/A3/25/2026Q4 2025CTSOCytosorbents-$0.05-$0.09-$0.04-$0.09$9.22 million$9.23 million3/24/2026Q4 2025TELATELA Bio-$0.18-$0.16+$0.02-$0.17$21.04 million$20.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/ARCARRenovaCareN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/AVAPOVapothermN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents2.822.131.58RCARRenovaCareN/AN/AN/ATELATELA Bio8.824.203.59VAPOVapothermN/A0.250.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%RCARRenovaCareN/ATELATELA Bio94.35%VAPOVapotherm43.08%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%RCARRenovaCare0.86%TELATELA Bio4.70%VAPOVapotherm15.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.70 million58.12 millionOptionableRCARRenovaCare1N/AN/ANot OptionableTELATELA Bio12044.77 million42.66 millionOptionableVAPOVapotherm2906.26 million5.27 millionNo DataTELA, CTSO, VAPO, and RCAR HeadlinesRecent News About These CompaniesVapotherm(R) Announces FDA 510(k) Clearance for the All Patient Circuit(TM), Enabling High Velocity Therapy for Neonatal to Adult PatientsApril 22, 2026 | marketwatch.comVapotherm® Announces FDA 510(k) Clearance for the All Patient Circuit™, Enabling High Velocity Therapy for Neonatal to Adult PatientsApril 21, 2026 | uk.finance.yahoo.comVapotherm and Flight Medical to introduce VentO₂ux ventilator for US hospitalsDecember 10, 2025 | msn.comVapotherm and Flight Medical Announce Partnership to Bring the VentO2ux(TM) Ventilator to US HospitalsDecember 9, 2025 | marketwatch.comVapotherm HVT® 2.0 Earns DoD Authority to Operate Certification, Advancing Secure Respiratory Support for Military and VA HospitalsOctober 28, 2025 | tmcnet.comNew Study Confirms Vapotherm's Unicorn™ Cannula Provides Comparable Efficacy at Lower Flow RatesMay 20, 2025 | finance.yahoo.comGlobal High-Flow Oxygen Therapy Devices Market Set to Reach USD 1,567.2 Million by 2033 Amid Rising Demand for Respiratory Care Solutions | FMIOctober 25, 2024 | fmiblog.comFGlobal Active Humidifier Devices Market Projects Modest Decline Amid Shifting Respiratory Care Landscape | FMIOctober 25, 2024 | fmiblog.comFDecline Looms Over Global High Flow Nasal Cannula Market to reach USD 1,063.0 Million by 2034: A Call for Innovation and Adaptation | FMIOctober 21, 2024 | fmiblog.comFGlobal Endobronchial Valves Market Expected to Experience Strong Growth by 2031 | Exactitude ConsultancySeptember 24, 2024 | finance.yahoo.comVapotherm, Inc.: Vapotherm Announces Closing of MergerSeptember 20, 2024 | finanznachrichten.deVapotherm Announces Closing of MergerSeptember 20, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VAPO, SGE, RPHM, SQSP on Behalf of ShareholdersAugust 30, 2024 | stockhouse.comVAPO Stock Earnings: Vapotherm Reported Results for Q2 2024August 13, 2024 | msn.comVapotherm Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | prnewswire.comPLPL Plandaí Biotechnology, Inc.July 28, 2024 | seekingalpha.comVA20.SG,0P0001F4D7,0 (VA20.SG)July 23, 2024 | finance.yahoo.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Vapotherm, Inc. - VAPOJuly 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Vapotherm, Inc. – VAPOJuly 8, 2024 | globenewswire.comThe Schall Law Firm Is Performing A Scrutiny Into Vapotherm Inc And Welcomes Investors Of VAPO To EngageJuly 1, 2024 | accesswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTELA, CTSO, VAPO, and RCAR Company DescriptionsCytosorbents NASDAQ:CTSO$0.61 +0.04 (+6.93%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$0.61 +0.00 (+0.25%) As of 05/7/2026 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.RenovaCare OTCMKTS:RCARRenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.TELA Bio NASDAQ:TELA$1.10 +0.11 (+11.11%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$1.11 +0.01 (+0.91%) As of 05/7/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Vapotherm NYSE:VAPOVapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
